{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T03:41:57Z","timestamp":1769053317360,"version":"3.49.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019120","name":"Otsuka America","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019120","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1053\/j.ajkd.2013.07.004","type":"journal-article","created":{"date-parts":[[2013,8,26]],"date-time":"2013-08-26T08:01:09Z","timestamp":1377504069000},"page":"1046-1057","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Patient-Reported Outcomes in Clinical Trials of CKD-Related Therapies: Report of a Symposium Sponsored by the National Kidney Foundation and the US Food and Drug Administration"],"prefix":"10.1053","volume":"62","author":[{"given":"Ronald D.","family":"Perrone","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen Joel","family":"Coons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerri","family":"Cavanaugh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fred","family":"Finkelstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klemens B.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1053\/j.ajkd.2013.07.004_bib1","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2215\/CJN.00630208","article-title":"Health-related quality of life and hemoglobin levels in chronic kidney disease patients","volume":"4","author":"Finkelstein","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.ajkd.2013.07.004_bib2","doi-asserted-by":"crossref","first-page":"252","DOI":"10.2215\/CJN.07231009","article-title":"A\u00a0comparison of SF-36 and SF-12 composite scores and subsequent hospitalization and mortality risks in long-term dialysis patients","volume":"5","author":"Lacson","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2013.07.004_bib3","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1046\/j.1523-1755.2003.00072.x","article-title":"Health-related quality of life as a predictor of mortality and hospitalization: the Dialysis Outcomes and Practice Patterns Study (DOPPS)","volume":"64","author":"Mapes","year":"2003","journal-title":"Kidney Int"},{"issue":"24","key":"10.1053\/j.ajkd.2013.07.004_bib4","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1056\/NEJMoa1001593","article-title":"In-center hemodialysis six times per week versus three times per week","volume":"363","author":"Chertow","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1053\/j.ajkd.2013.07.004_bib5","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1053\/j.ajkd.2010.04.019","article-title":"Effect of daily hemodialysis on depressive symptoms and postdialysis recovery time: interim report from the FREEDOM (Following Rehabilitation, Economics and Everyday-Dialysis Outcome Measurements) Study","volume":"56","author":"Jaber","year":"2010","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"10.1053\/j.ajkd.2013.07.004_bib6","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.2215\/CJN.10451110","article-title":"Impact of short daily hemodialysis on restless legs symptoms and sleep disturbances","volume":"6","author":"Jaber","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2013.07.004_bib7","unstructured":"U.S. Code of Federal Regulations. 21 CFR 314.126. Vol 52011. (2011)."},{"key":"10.1053\/j.ajkd.2013.07.004_bib8","unstructured":"US Food and Drug Administration. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims. 2009. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM193282.pdf. Accessed February 11,\u00a02011."},{"issue":"26","key":"10.1053\/j.ajkd.2013.07.004_bib9","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMp1011024","article-title":"What is value in health care?","volume":"363","author":"Porter","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.ajkd.2013.07.004_bib10","unstructured":"National Institute of Health. Patient Reported Outcomes Measurement Information System (PROMIS). www.nihpromis.org. Accessed October 19,\u00a02012."},{"issue":"5","key":"10.1053\/j.ajkd.2013.07.004_bib11","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1681\/ASN.V85824","article-title":"Treatment of the idiopathic nephrotic syndrome: regimens and outcomes in children and adults","volume":"8","author":"Tune","year":"1997","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"7654","key":"10.1053\/j.ajkd.2013.07.004_bib12","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1136\/bmj.39576.709711.80","article-title":"Nephrotic syndrome in adults","volume":"336","author":"Hull","year":"2008","journal-title":"BMJ"},{"issue":"2","key":"10.1053\/j.ajkd.2013.07.004_bib13","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1053\/j.ajkd.2009.04.029","article-title":"Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food\u00a0and Drug Administration","volume":"54","author":"Levey","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2013.07.004_bib14","series-title":"Primer on Kidney Diseases","first-page":"148","article-title":"Glomerular clinicopathologic syndromes","author":"Jennette","year":"2009"},{"issue":"17","key":"10.1053\/j.ajkd.2013.07.004_bib15","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1056\/NEJM199804233381707","article-title":"The nephrotic syndrome","volume":"338","author":"Orth","year":"1998","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1053\/j.ajkd.2013.07.004_bib16","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/ki.2010.485","article-title":"Clinical trials treating focal segmental glomerulosclerosis should measure patient quality of life","volume":"79","author":"Gipson","year":"2011","journal-title":"Kidney Int"},{"issue":"5","key":"10.1053\/j.ajkd.2013.07.004_bib17","doi-asserted-by":"crossref","first-page":"e37763","DOI":"10.1371\/journal.pone.0037763","article-title":"Proteinuria is associated with quality of life and depression in adults with primary glomerulopathy and preserved renal function","volume":"7","author":"Liborio","year":"2012","journal-title":"PLoS One"},{"issue":"1-2","key":"10.1053\/j.ajkd.2013.07.004_bib18","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3121\/cmr.2009.819","article-title":"Reliability and feasibility of methods to quantitatively assess peripheral edema","volume":"7","author":"Brodovicz","year":"2009","journal-title":"Clin Med Res"},{"issue":"5","key":"10.1053\/j.ajkd.2013.07.004_bib19","doi-asserted-by":"crossref","first-page":"960","DOI":"10.2215\/CJN.00990207","article-title":"Renal provider recognition of symptoms in patients on maintenance hemodialysis","volume":"2","author":"Weisbord","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"10.1053\/j.ajkd.2013.07.004_bib20","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2215\/CJN.00430109","article-title":"Symptom burden, depression, and quality of life in chronic and end-stage kidney disease","volume":"4","author":"Abdel-Kader","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2013.07.004_bib21","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1093\/ndt\/gfp426","article-title":"Developing a self-administered CKD symptom assessment instrument","volume":"25","author":"Agarwal","year":"2010","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1053\/j.ajkd.2013.07.004_bib22","doi-asserted-by":"crossref","first-page":"e349","DOI":"10.1542\/peds.2009-0085","article-title":"Health-related quality of life of children with mild to moderate chronic kidney disease","volume":"125","author":"Gerson","year":"2010","journal-title":"Pediatrics"},{"key":"10.1053\/j.ajkd.2013.07.004_bib23","unstructured":"Rare Disease in Clinical Health Network. https:\/\/rarediseasesnetwork.epi.usf.edu\/NEPTUNE. Accessed August 6, 2013."},{"key":"10.1053\/j.ajkd.2013.07.004_bib24","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S0140-6736(07)60601-1","article-title":"Autosomal dominant polycystic kidney disease","volume":"369","author":"Torres","year":"2007","journal-title":"Lancet"},{"issue":"20","key":"10.1053\/j.ajkd.2013.07.004_bib25","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1056\/NEJMoa054341","article-title":"Volume progression in polycystic kidney disease","volume":"354","author":"Grantham","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.ajkd.2013.07.004_bib26","doi-asserted-by":"crossref","first-page":"148","DOI":"10.2215\/CJN.00330705","article-title":"Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes","volume":"1","author":"Grantham","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.ajkd.2013.07.004_bib27","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1046\/j.1523-1755.2001.00985.x","article-title":"Pain management in polycystic kidney disease","volume":"60","author":"Bajwa","year":"2001","journal-title":"Kidney Int"},{"issue":"3","key":"10.1053\/j.ajkd.2013.07.004_bib28","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1053\/ajkd.2002.31407","article-title":"Renal contraction therapy for enlarged polycystic kidneys by transcatheter arterial embolization in hemodialysis patients","volume":"39","author":"Ubara","year":"2002","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1053\/j.ajkd.2013.07.004_bib29","doi-asserted-by":"crossref","first-page":"560","DOI":"10.2215\/CJN.02410508","article-title":"Quality of life in autosomal dominant polycystic kidney disease patients not yet on dialysis","volume":"4","author":"Rizk","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2013.07.004_bib30","unstructured":"LeBeau K. Anemia related to kidney disease. Paper presented at: MEDCAC Meeting. March 24,\u00a02010; Baltimore, MD."},{"issue":"6","key":"10.1053\/j.ajkd.2013.07.004_bib31","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1681\/ASN.2009121302","article-title":"Sirolimus therapy to halt the progression of ADPKD","volume":"21","author":"Perico","year":"2010","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"9","key":"10.1053\/j.ajkd.2013.07.004_bib32","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1056\/NEJMoa0907419","article-title":"Sirolimus and kidney growth in autosomal dominant polycystic kidney disease","volume":"363","author":"Serra","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"10.1053\/j.ajkd.2013.07.004_bib33","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1053\/j.ajkd.2013.07.004_bib34","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1053\/j.ajkd.2010.11.029","article-title":"Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes) 3-4 Study","volume":"57","author":"Torres","year":"2011","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"10.1053\/j.ajkd.2013.07.004_bib35","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1053\/j.gastro.2009.07.052","article-title":"Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial","volume":"137","author":"van Keimpema","year":"2009","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1053\/j.ajkd.2013.07.004_bib36","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1056\/NEJMoa1003491","article-title":"Everolimus in patients with autosomal dominant polycystic kidney disease","volume":"363","author":"Walz","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.ajkd.2013.07.004_bib37","unstructured":"Scott N. ESAs in anemia related to kidney disease. Paper presented at: MEDCAC Meeting; March 24,\u00a02010."},{"issue":"3","key":"10.1053\/j.ajkd.2013.07.004_bib38","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2215\/CJN.09500911","article-title":"Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease","volume":"7","author":"Chapman","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"issue":"12","key":"10.1053\/j.ajkd.2013.07.004_bib39","doi-asserted-by":"crossref","first-page":"992","DOI":"10.7326\/0003-4819-111-12-992","article-title":"Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial","volume":"111","author":"Eschbach","year":"1989","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1053\/j.ajkd.2013.07.004_bib40","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1001\/jama.1990.03440060071035","article-title":"The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. Cooperative Multicenter EPO Clinical Trial Group","volume":"263","author":"Evans","year":"1990","journal-title":"JAMA"},{"issue":"20","key":"10.1053\/j.ajkd.2013.07.004_bib41","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1056\/NEJMoa065485","article-title":"Correction of anemia with epoetin alfa in chronic kidney disease","volume":"355","author":"Singh","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"20","key":"10.1053\/j.ajkd.2013.07.004_bib42","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa062276","article-title":"Normalization of hemoglobin level in patients with chronic kidney disease and anemia","volume":"355","author":"Drueke","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.ajkd.2013.07.004_bib43","unstructured":"Paper presented at: Cardiovascular and Renal Drugs Advisory Committee (CRDAC) in Joint Session with Drug Safety and Risk Management Advisory Committee (DSARM); September 11, 2007; Gaithersburg, MD."},{"key":"10.1053\/j.ajkd.2013.07.004_bib44","unstructured":"Hartwell L. Risks and benefits of ESAs in chronic renal failure. Paper presented at: 2007 Joint Session of FDA CRDAC and DSaRM. September 11,\u00a02007; Gaithersburg, MD."},{"issue":"3","key":"10.1053\/j.ajkd.2013.07.004_bib45","doi-asserted-by":"crossref","first-page":"A31","DOI":"10.1053\/j.ajkd.2010.01.005","article-title":"TREAT versus treatment: a patient's view of a scientific interpretation","volume":"55","author":"Prisant","year":"2010","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1053\/j.ajkd.2013.07.004_bib46","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1681\/ASN.2009111127","article-title":"Does TREAT give the boot to ESAs in the treatment of CKD anemia?","volume":"21","author":"Singh","year":"2010","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2013.07.004_bib47","doi-asserted-by":"crossref","first-page":"23","DOI":"10.7326\/0003-4819-153-1-201007060-00252","article-title":"Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease","volume":"153","author":"Palmer","year":"2010","journal-title":"Ann Intern Med"},{"issue":"12","key":"10.1053\/j.ajkd.2013.07.004_bib48","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1001\/archinternmed.2009.112","article-title":"The impact of selecting a high hemoglobin target level on health-related quality of life for patients with chronic kidney disease: a systematic review and meta-analysis","volume":"169","author":"Clement","year":"2009","journal-title":"Arch Intern Med"},{"issue":"3","key":"10.1053\/j.ajkd.2013.07.004_bib49","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1053\/j.ajkd.2009.09.019","article-title":"Impact of erythropoiesis-stimulating agents on energy and physical function in nondialysis CKD patients with anemia: a systematic review","volume":"55","author":"Gandra","year":"2010","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"10.1053\/j.ajkd.2013.07.004_bib50","first-page":"279","article-title":"KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"issue":"4","key":"10.1053\/j.ajkd.2013.07.004_bib51","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0272-6386(04)00939-4","article-title":"How strong are patients' preferences in choices between dialysis modalities and doses?","volume":"44","author":"Bass","year":"2004","journal-title":"Am\u00a0J Kidney Dis"},{"key":"10.1053\/j.ajkd.2013.07.004_bib52","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/1745-6215-11-85","article-title":"Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal","volume":"11","author":"Kent","year":"2010","journal-title":"Trials"},{"issue":"5","key":"10.1053\/j.ajkd.2013.07.004_bib53","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/clpt.2011.203","article-title":"The Patient-Reported Outcome (PRO) Consortium: filling measurement gaps for PRO end points to support labeling claims","volume":"90","author":"Coons","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1053\/j.ajkd.2013.07.004_bib54","unstructured":"US Food and Drug Administration. Guidance for industry: qualification process for drug development tools (draft). 2010. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM230597.pdf. Accessed August 3,\u00a02012."},{"key":"10.1053\/j.ajkd.2013.07.004_bib55","unstructured":"Coons SJ, Burke LB. Patient-reported outcome instruments\u00a0as\u00a0drug development tools. http:\/\/www.c-path.org\/Events\/creating_consensus_science\/session3_patient_reported_outcomes_instruments_as_tools.pdf?&lang=en_us&output=json. Accessed July 22,\u00a02013."},{"key":"10.1053\/j.ajkd.2013.07.004_bib56","unstructured":"Critical Path Institute. Patient-Reported Outcome (PRO) Consortium. www.c-path.org\/PRO.cfm. Accessed July 22,\u00a02013."}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638613010743?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638613010743?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T02:13:42Z","timestamp":1759457622000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638613010743"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":56,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S0272638613010743"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2013.07.004","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient-Reported Outcomes in Clinical Trials of CKD-Related Therapies: Report of a Symposium Sponsored by the National Kidney Foundation and the US Food and Drug Administration","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2013.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}